Rituximab

Uses in Dermatology

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Rituximab is an anti-CD20 monoclonal antibody with considerable potential in dermatology due to an increase in off-label indications. Chronic graft-versus-host disease and pemphigus vulgaris are two of the most promising indications for off-label use of rituximab. It is a generally safe alternative that should be considered when traditional therapy with corticosteroids or immunosuppressants has failed or caused significant intolerance. Currently, rituximab is only FDA-approved for treatment of follicular and diffuse large B-cell non-Hodgkin's lymphoma, rheumatoid arthritis, chronic lymphocytic leukemia, granulomatosis with polyangiitis (formerly Wegener's granulomatosis) and microscopic polyangiitis. Herein, off-label uses of rituximab and its efficacy in the treatment of cutaneous diseases are reviewed.

Original languageEnglish (US)
Pages (from-to)5-7
Number of pages3
JournalSkin therapy letter
Volume21
Issue number5
StatePublished - Sep 1 2016

Fingerprint

Dermatology
Off-Label Use
Granulomatosis with Polyangiitis
Microscopic Polyangiitis
Pemphigus
B-Cell Lymphoma
Graft vs Host Disease
B-Cell Chronic Lymphocytic Leukemia
Immunosuppressive Agents
Skin Diseases
Non-Hodgkin's Lymphoma
Rheumatoid Arthritis
Adrenal Cortex Hormones
Monoclonal Antibodies
Rituximab
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Rituximab : Uses in Dermatology. / Gleghorn, K.; Wilson, Janice; Wilkerson, Michael.

In: Skin therapy letter, Vol. 21, No. 5, 01.09.2016, p. 5-7.

Research output: Contribution to journalReview article

@article{ed3e6da5a3644cafbbb584195366ea0f,
title = "Rituximab: Uses in Dermatology",
abstract = "Rituximab is an anti-CD20 monoclonal antibody with considerable potential in dermatology due to an increase in off-label indications. Chronic graft-versus-host disease and pemphigus vulgaris are two of the most promising indications for off-label use of rituximab. It is a generally safe alternative that should be considered when traditional therapy with corticosteroids or immunosuppressants has failed or caused significant intolerance. Currently, rituximab is only FDA-approved for treatment of follicular and diffuse large B-cell non-Hodgkin's lymphoma, rheumatoid arthritis, chronic lymphocytic leukemia, granulomatosis with polyangiitis (formerly Wegener's granulomatosis) and microscopic polyangiitis. Herein, off-label uses of rituximab and its efficacy in the treatment of cutaneous diseases are reviewed.",
author = "K. Gleghorn and Janice Wilson and Michael Wilkerson",
year = "2016",
month = "9",
day = "1",
language = "English (US)",
volume = "21",
pages = "5--7",
journal = "Skin therapy letter",
issn = "1201-5989",
publisher = "International Skin Therapy Newsletter, Inc.",
number = "5",

}

TY - JOUR

T1 - Rituximab

T2 - Uses in Dermatology

AU - Gleghorn, K.

AU - Wilson, Janice

AU - Wilkerson, Michael

PY - 2016/9/1

Y1 - 2016/9/1

N2 - Rituximab is an anti-CD20 monoclonal antibody with considerable potential in dermatology due to an increase in off-label indications. Chronic graft-versus-host disease and pemphigus vulgaris are two of the most promising indications for off-label use of rituximab. It is a generally safe alternative that should be considered when traditional therapy with corticosteroids or immunosuppressants has failed or caused significant intolerance. Currently, rituximab is only FDA-approved for treatment of follicular and diffuse large B-cell non-Hodgkin's lymphoma, rheumatoid arthritis, chronic lymphocytic leukemia, granulomatosis with polyangiitis (formerly Wegener's granulomatosis) and microscopic polyangiitis. Herein, off-label uses of rituximab and its efficacy in the treatment of cutaneous diseases are reviewed.

AB - Rituximab is an anti-CD20 monoclonal antibody with considerable potential in dermatology due to an increase in off-label indications. Chronic graft-versus-host disease and pemphigus vulgaris are two of the most promising indications for off-label use of rituximab. It is a generally safe alternative that should be considered when traditional therapy with corticosteroids or immunosuppressants has failed or caused significant intolerance. Currently, rituximab is only FDA-approved for treatment of follicular and diffuse large B-cell non-Hodgkin's lymphoma, rheumatoid arthritis, chronic lymphocytic leukemia, granulomatosis with polyangiitis (formerly Wegener's granulomatosis) and microscopic polyangiitis. Herein, off-label uses of rituximab and its efficacy in the treatment of cutaneous diseases are reviewed.

UR - http://www.scopus.com/inward/record.url?scp=85016924278&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85016924278&partnerID=8YFLogxK

M3 - Review article

VL - 21

SP - 5

EP - 7

JO - Skin therapy letter

JF - Skin therapy letter

SN - 1201-5989

IS - 5

ER -